Cyclosporin H

Research use only, not for human use.

Cyclosporin H (CsH), a specific inhibitor of FPR1, inhibited lung inflammation in the ALI models.

Cyclosporin H (CsH), a specific inhibitor of FPR1, inhibited lung inflammation in the ALI models. CsH significantly attenuated MTDs or NFP-induced inflammatory lung injury and activation of MAPK and AKT pathways. Cyclosporin H is a viral transduction enhancer which increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). When combined with Rapamycin or Prostaglandin E2 Cyclosporin H displays an additive effect. Cyclosporin H lacks immunosuppressant activity of Cyclosporin A.(In Vitro):Cyclosporin H is a potent inhibitor of FMLP-induced superoxide anion (O2-) formation in human neutrophils. Cyclosporin H inhibited FMLP binding in HL-60 membranes with a Ki (inhibition constant) of 0.10 μM. Cyclosporin H inhibited activation by FMLP of high affinity GTPase (the enzymatic activity of alpha-subunits of heterotrimeric regulatory guanine nucleotide-binding proteins) in HL-60 membranes with a Ki of 0.79 μM. Cyclosporin H inhibited the stimulatory effects of FMLP on cytosolic Ca2+ concentration ([Ca2+]i), O2- formation, and beta-glucuronidase release with Ki values of 0.08, 0.24, and 0.45 μM, respectively.(In Vivo):Cyclosporin H (5 mg/kg; i.p.; before LPS or HCl challenge) attenuats lung injury induced by LPS or HCl (a lung injurymodel).

——

——

——

Others

Other Targets

AXL

——

——

83602-39-5

1202.61

C62H111N11O12

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (83.15 mM)

CN(C(C(CC(C)C)N(C)C(C(C)NC(C(C)NC(C(CC(C)C)N(C)C(C(C(C)C)NC(C(N1C)CC(C)C)=O)=O)=O)=O)=O)=O)C(CC(C)C)C(N(C)C(C(C)C)C(N(C)C(C(O)C(C)C/C=C/C)C(NC(CC)C(N(C)CC1=O)=O)=O)=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years